News
Clinical Trials Arena on MSN1d
Vertex’s Journavx successor culled after falling short in Phase II trialTopline results reveal that VX-993 did not meet its primary endpoints, meaning Vertex will discontinue its development.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback